IL2 and atherosclerosis: After Webster et al. succeeded in expanding Tregs by administering interleukin (IL)-2 along with IL-2 mAb to mice [51], preclinical studies have used the IL-2/anti-IL-2 mAb treatment to expand Tregs and have demonstrated their efficacy in suppressing both the development of atherosclerosis as well as the advancement of developed atherosclerosis [52].